Compare Ionis Pharmaceuticals Inc. Common Stock (IONS) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ionis Pharmaceuticals Inc. Common Stock vs Raytheon Technologies Corp — how do they compare? Ionis Pharmaceuticals Inc. Common Stock trades at $43.2 (market cap $7.04B), while Raytheon Technologies Corp trades at $188.47 (market cap $246.67B). The key difference: Raytheon Technologies Corp is far larger — about 35× Ionis Pharmaceuticals Inc. Common Stock's market cap, and Raytheon Technologies Corp pays a 1.6% dividend while Ionis Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ionis Pharmaceuticals Inc. Common Stock for 0 Days and Raytheon Technologies Corp for 78 Days on average.
| IONS | RTX | |
|---|---|---|
Market Cap | $7.04B | $246.67B |
Volume | 2,977,440 | 4,726,714 |
Sector | Health | Industrials |
52-Week High | $86.50 | $225.49 |
52-Week Low | $42.38 | $157.00 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $6.60B | $277.22B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RTX trades at $183.02, down 1.95% today, amid a bearish technical signal. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.89 exceeding the $1.66 estimate. Revenue grew to $88.60 billion in 2025, and the net income margin improved to 7.59%. A robust $289 billion backlog and positive defense budget trends underpin growth prospects, though elevated debt levels and a high P/E ratio of 32.22 present valuation concerns.
The outlook remains positive given analyst consensus, with a $233.55 price target implying significant upside. Key opportunities include sustained defense demand and commercial aerospace recovery. Risks involve execution on the large backlog, interest expense from debt, and geopolitical uncertainties affecting defense spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ionis Pharmaceuticals Inc. Common Stock
Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
